前不久，中国药品价格登记系统正式上线，9家国内外头部药企完成首批药品价格登记。该系统独立于 各省级医药采购平台，将为企业提供权威、规范、透明的市场价格登记查询服务，是企业构建全球化、 多元化价格体系的展示平台，对医药创新发展具有重要意义。 近年来，我国医药产业创新能力显著增强，对很多药企来说，创新药出海从可选项变成了必选项。2025 年前三季度，中国医药企业完成海外交易103笔，总交易金额突破920亿美元。 放眼全球，一些国家和地区在审批药品准入时，往往要求其提供原研国的价格作为国际参考定价。但对 我国一些药企而言，由于医保支付价格通常较低，药品纳入医保后，其价格往往难以体现创新药的市场 价值。同时，药品其他非医保渠道的价格又没有凭证，导致海外市场难以找到可靠的定价依据。类似困 扰在众多出海药企中普遍存在，一定程度上制约了国产创新药产业国际化发展。 医药创新发展关乎人民群众健康福祉，更关乎国家生物医药产业的核心竞争力。中国药品价格登记系 统，填补了国家层面价格信息平台的空白，是创新药企打破出海壁垒、撬动全球市场的一个重要支点。 当前，美国、欧盟等发达国家和地区均在推进药品价格管控。合理的登记价格水平，能帮助本 ...

如何保障药品登记价格的真实、合理？常峰分析说，一方面，申报价格需基于真实、合理的市场交易， 要求企业对其全球价格策略与市场信誉负责；另一方面，登记价格面向企业和全球开放查询，受企业之 间、国际市场的广泛监督，虚高、失实的价格将难以获得市场认可。"中国药登在尊重企业自主申报的 同时，借助公开监督与市场约束，保障药品价格的真实性与合理性。" 今天的中国已成为全球药物创新的重要来源，正通过一系列政策与措施，支持医药企业创新发展。中国 药登正式上线也被业内视为支持创新药发展的一项"基础设施"。 解读药品价格登记系统：赋予中国创新药国际市场"新身份" 中新社北京12月4日电 (记者 李纯)中国药品价格登记系统(简称"中国药登")近日正式上线。该系统的启 动被视为助力中国创新药"走出去"，吸引更多国外高质量新药进入中国市场的有力举措。 中国药科大学国际医药商学院院长常峰4日接受中新社记者采访时表示，中国药登着眼于为企业提供面 向全球的权威、规范、透明的市场价格登记查询服务，帮助企业构建全球化、多元化的药品价格体系， 赋予中国创新药在国际市场上的"新身份"。 在该系统上线之前，中国的药品价格体系以省级医药采购平台价格为主。 ...

Group 1 - The core point of the news is that Baihua Pharmaceutical's controlling shareholder and actual controllers have their agreement to act in concert expire, which will not adversely affect the company's management or change its controlling shareholder [1] - The expiration of the agreement is a routine corporate governance action, and the company confirms that it will not impact daily operations [1] - Such agreements not being renewed after expiration is common in the A-share market [1] Group 2 - YKYY018 aerosol inhalation agent from Yuyuan Pharmaceutical has received clinical trial approval from both Chinese and U.S. regulatory authorities for the prevention and treatment of respiratory syncytial virus (RSV) infections [2] - This product addresses a significant clinical need, particularly in high-risk populations, and utilizes an innovative aerosol inhalation delivery method [2] Group 3 - HeYu Pharmaceutical's oral small molecule KRAS G12D inhibitor, ABSK141, has received IND approval from the U.S. FDA for treating patients with advanced solid tumors carrying the KRAS G12D mutation [3] - This drug targets a common oncogenic mutation associated with several cancers, including pancreatic and colorectal cancer, indicating a pressing clinical demand [3] Group 4 - The China Drug Price Registration System has been officially launched, aimed at providing authoritative and accurate drug price information to support the internationalization of pharmaceutical companies [4] - This system is a key step towards establishing a scientific and transparent pricing system for innovative drugs in China, facilitating high-quality development in the pharmaceutical industry [4]

Group 1 - The article discusses the recent developments in the investment banking sector, highlighting the impact of economic changes on market dynamics [1] - It emphasizes the importance of adapting strategies to navigate the evolving financial landscape, particularly in response to regulatory changes and market volatility [1] - The report indicates a significant increase in mergers and acquisitions activity, with a notable rise of 25% in deal volume compared to the previous year [1] Group 2 - The analysis points out that technology integration is becoming a key driver for investment banks, with firms investing heavily in digital platforms to enhance client services [1] - It also mentions the growing trend of sustainable finance, with a 30% increase in green bond issuance, reflecting a shift towards environmentally responsible investing [1] - The article concludes by forecasting continued growth in the sector, driven by innovation and changing investor preferences [1]